Clinical trial
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
NCT01631552 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT01631552 |
|---|---|
| Title | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer |
| Official title | A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer and 6 more |
| Intervention type | Drug |
| Interventions | Sacituzumab Govitecan-hziy (SG) |
| Enrollment | 515 |
| Start date | Dec 17, 2012 |
| Primary completion | Mar 1, 2019 |
| Completion | Aug 13, 2020 |
| First posted | Jun 29, 2012 |
| Last update posted | Aug 12, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: